20Jan 2017

ARGINASE ENZYME ACTIVITY AND LACTOFERRIN PROTEIN CONCENTRATION IN EGYPTIAN DIABETIC PATIENTS.

  • Faculty of Science, Cairo University, Department of Chemistry, Lab of Biochemistry.
  • Faculty of Science, Cairo University, Department of Chemistry.
  • NationalDiabetes and Endocrinology Institute.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Purpose: This work has been carried out to evaluate the arginase activity andlactoferrin (LF) level as biochemical markers in type 2 diabetic Egyptian. Subjects and Methods: The present study consisted of 84 patients classified into threegroups: Uncontrolled diabetic patients [G1], Control diabetic patients [G2], Normal healthy subjects [G3]. Lactoferrin concentration was measured using ELISA technique. Arginase andother biochemical parameters were measured by using Jenway 6105 uv/vis spectrophotometer. Finally, all the results were statistically analyzed andcompared with normal subjects [G3]. Results: The mean sera value of both arginase and LF was found to beelevated in uncontrolled type 2 diabeticpatient group[G1] and controlled type 2 diabetic patientgroup[G2] compared to normal healthygroup [G3]. Conclusion: Both arginase and LF are considered as good biomarkers fordiagnosis of type 2 diabetes and for detection of the best and most effectivemethod for the treatment.


  1. You H., Bo P., Sunmin P., Sung-HoonK.(2011): A Comparative Study of Eating Habits and Food Intake in Women with Gestational Diabetes according to Early Postpartum Glucose Tolerance Status. Diabetes Metab. J., 35:354-363.
  2. Britney G., Mary S., James T., Lily W., Phil D., Joy J., Pamela F., Priyaanka N., George E., and Thomas A. (2010): Genome-Wide Analysis of Copy Number Variation in Type 1 Diabetes. Plos One, 5(11): 1-8.
  3. Wu G and Morris SM. (1998): Arginine metabolism:nitric oxide and beyond. The Biochemical Journal 336 (Pt1): 1–17.
  4. Sharma S, Sinha M, Kaushik S, Kaur P, Singh TP. (2013):C-lobe of lactoferrin: the whole story of the half-molecule. Res. Int., 2013:271641.
  5. Fruzsina J., Robert J., Kelly P., Ahmad S. and William D. (2013): Arginase promotes skeletal muscle arteriolar endothelial dysfunction in diabetic rats. Immunology, 4(119): 1-7.
  6. Jelodar G, Razmi N, Gholampour V. (2007): Arginase alteration in the reproductive system of alloxan-diabetic dogs. Reprod. Dev., 53(2):317-321.
  7. Jochen S., Daniel N., and Dan B. (2013): Development of novel arginase inhibitors for therapy of endothelial dysfunction. Immunology, 4(278): 1-6.
  8. Seraf?´n R.-Z., Miguel M.-R., Marisela O., Lourdes S.-S., Miguel Q.-Q., Norberto G.-G., Rolando H.-M. (2013): Increased Erythrocytes By-Products of Arginine Catabolism Are Associated with Hyperglycemia and Could Be Involved in the Pathogenesis of Type 2 Diabetes Mellitus. PLOS ONE, 8 (6):e66823.
  9. Salimuddin, Kailash U., and Najma B. (1999): Effects of Vanadate on Expression of Liver Arginase in Experimental Diabetic Rats. IUBMB Life, 48: 237–240.
  10. Jun-Ichi T., Hajime N., Katsuaki T., Masahiko I., Tadashi U., Atsushi N., Makoto N., Shinobu S., Toshifumi S., and Hisahiko S. (2002): Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J. Physiol. Gastrointest. Liver Physiol., 283: G187–G195.
  11. Moreno-Navarrete J. M., Ortega F.J., Bassols J., Ricart W., and Ferna´ndez-Real J. M. (2009): Decreased Circulating Lactoferrin in Insulin Resistance and Altered Glucose Tolerance as a Possible Marker of Neutrophil Dysfunction in Type 2 Diabetes. Clin. Endocrinol.Metab., 94: 4036–4044.
  12. Jose´ M.-N., Francisco O., Judit B., Antoni C., Wifredo R., and Jose´ F.-R. (2008): Association of Circulating Lactoferrin Concentration and 2 NonsynonymousLTF Gene Polymorphisms with Dyslipidemia in Men Depends on Glucose-Tolerance Status. Clinical Chemistry, 54(2):301–309.
  13. Beata N., Marcin F., Tomasz K., Maja K., Micha Z. (2010): Lactoferrin inhibits the growth of nasal polypfibroblasts. Pharmacoligical Reports, 62: 1139-1147.
  14. Ben-Aryeh H., Serouya R. Kanter Y., Szargel R., and Laufer D. (1993): Oral health and salivary composition in diabetic patients. Diabetes Complications, 7(1):57-62.
  15. José F., Eduardo G.-F., José M.-N., Mora M.-P., Lourdes G.-S., Wifredo R., and Francisco T. (2010): Fat Overload Induces Changes in Circulating Lactoferrin That Are Associated with Postprandial Lipemia and Oxidative Stress in Severely Obese Subjects. Obesity, 18: 482–488.
  16. Dodds M.W., Yeh C.K., and Johnson D.A. (2000): Salivary alterations in type 2 (non-insulin dependent) diabetes mellitus and hypertension. Community Dent. Oral Epidemiol., 28(5): 373-381.
  17. Vengen I.T., Dale A.C., Wiseth R., Midthjell K., and Videm V. (2010): Lactoferrin is a novel predicator of fatal ischemic heart disease in diabetes mellitus type 2: long-term follow-up of the HUNT1 study. Atherosclerosis, 212(2): 614-620.
  18. Artym J. (2012):A remedy against obesity? The role of lactoferrin in the metabolism of glucose and lipids.Hig. Med. Dosw. (Online)., 66:937-953.

[Mohamed A. El-Desouky, Sanaa Osman, Nashwa M. Shams Eldin and IbrahimEmaraa. (2017); ARGINASE ENZYME ACTIVITY AND LACTOFERRIN PROTEIN CONCENTRATION IN EGYPTIAN DIABETIC PATIENTS. Int. J. of Adv. Res. 5 (1). 1518-1523] (ISSN 2320-5407). www.journalijar.com


Nashwa M. Shams Eldin
Faculty of Science, Cairo University, Department of Chemistry, Lab of Biochemistry

DOI:


Article DOI: 10.21474/IJAR01/2915       DOI URL: http://dx.doi.org/10.21474/IJAR01/2915


Share this article